Coronavirus: AMA releases vaccine CPT codes

New COVID-19 coronavirus vaccine-specific CPT codes have been released to enable physicians to properly report immunizations.

In a news release, the American Medical Association (AMA) says they worked closely with the U.S. Centers for Disease Control and Prevention and the CPT Panel to develop unique codes for two coronavirus vaccines. They also created administration codes unique to each. These will clinically distinguish each vaccine for better tracking, reporting, and analysis which will support data-driven planning and allocation.

“An effective national immunization program is key to bringing the coronavirus pandemic to an end,” AMA President Susan R. Bailey, MD, says in the release. “Correlating each coronavirus vaccine with its own unique CPT code provides analytical advantages to help track, allocate and optimize resources as an immunization program ramps up in the United States.”

According to the release, the new Category I CPT codes and long descriptions for vaccine products are:

• 91300 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use
• 91301 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use

The new vaccine administration CPT codes and long descriptions are:

• 0001A - Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose
• 0002A - Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose
• 0011A - Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose
• 0012A - Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose

The release says these new vaccine-specific CPT codes will be available for use and effective upon each new COVID-19 vaccine which receives emergency use authorization or approval from the Food and Drug Administration. Further information can be found on the AMA website.​